Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007-2018.
Li Z, Zhu G, Chen G, Luo M, Liu X, Chen Z, Qian J.
Lipids Health Dis. 2022 Oct 28;21(1):111. doi: 10.1186/s12944-022-01721-y.
MicroRNA in cardio-metabolic disorders.
Su X, Nie M, Zhang G, Wang B.
Clin Chim Acta. 2021 Jul;518:134-141. doi: 10.1016/j.cca.2021.03.024. Epub 2021 Apr 3.
Risk factors for cardiovascular diseases in patients with vitiligo: an analysis of current evidence.
Liang X, Guo F, Zhang M, Wang C, Lin N, Liu L, Chen Y, Liu F, Du Y, Li L, Li X.
Ann Med. 2024 Dec;56(1):2326297. doi: 10.1080/07853890.2024.2326297. Epub 2024 Sep 19.
Associations between various anthropometric indices and hypertension and hyperlipidaemia: a cross-sectional study in China.
Feng C, Lu C, Chen K, Song B, Shan Z, Teng W.
BMC Public Health. 2024 Nov 4;24(1):3045. doi: 10.1186/s12889-024-20505-w.
Hawthorn total flavonoids ameliorate hyperlipidemia through AMPK/SREBP1-c and PPARalpha/PGC-1alpha/CPT-1A pathway activation and gut microbiota modulation.
Zheng L, Lu Z, Ma Y, Cui P, Zhang X, Gan J, Li G.
J Sci Food Agric. 2025 Jun;105(8):4326-4337. doi: 10.1002/jsfa.14188. Epub 2025 Feb 27.
Prevalence and treatment of hyperlipidemia in patients with chronic hepatitis C infection.
Murthy GD, Vu K, Venugopal S.
Eur J Gastroenterol Hepatol. 2009 Aug;21(8):902-7. doi: 10.1097/MEG.0b013e32831b4698.
Triglyceride/high density lipoprotein cholesterol index and future cardiovascular events in diabetic patients without known cardiovascular disease.
Nakashima R, Ikeda S, Shinohara K, Matsumoto S, Yoshida D, Ono Y, Nakashima H, Miyamoto R, Matsushima S, Kishimoto J, Itoh H, Komuro I, Tsutsui H, Abe K.
Sci Rep. 2025 Mar 17;15(1):9217. doi: 10.1038/s41598-025-92933-6.
Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial.
Shah NN, Ghazi L, Yamamoto Y, Kumar S, Martin M, Simonov M, Riello Iii RJ, Faridi KF, Ahmad T, Wilson FP, Desai NR.
Circ Cardiovasc Qual Outcomes. 2024 May;17(5):e010335. doi: 10.1161/CIRCOUTCOMES.123.010335. Epub 2024 Apr 18.
Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia.
Zhao W, Cheng Z, Ji X, Pei Z, Yang K, Huang Z, Wu Y, Wang G, Wang M, Zhao Y, Bai X, Zhao S.
Nutr Metab Cardiovasc Dis. 2024 Sep;34(9):2217-2225. doi: 10.1016/j.numecd.2024.04.011. Epub 2024 Apr 24.
Effect of hyperlipidemia on the incidence of cardio-cerebrovascular events in patients with type 2 diabetes.
Fan D, Li L, Li Z, Zhang Y, Ma X, Wu L, Qin G.
Lipids Health Dis. 2018 May 8;17(1):102. doi: 10.1186/s12944-018-0676-x.
